pegylated orthogonal IL-2 STK-009

{
  "id": "MLC-T-ONC-015929",
  "term": "pegylated orthogonal IL-2 STK-009",
  "field": "Oncology and biomedicine",
  "definition": "A polyethylene glycol (PEG)-conjugated mutein form of the cytokine interleukin-2 (IL-2), with potential and specific activity on enhancing proliferation, survival and anti-tumor activity of engineered orthoIL-2Rb-expressing CAR T cells. Upon subcutaneous administration, pegylated orthogonal (ortho) IL-2 STK-009 specifically targets and binds to mutated orthoIL-2Rbeta (hoRbeta; hoRb) that is specifically expressed on certain engineered CAR T cells. This induces selective proliferation, survival, and cytotoxic function of orthoIL-2Rbeta-expressing CAR T cells, which enhances tumor cell killing and decreases tumor cell proliferation. Pegylation of IL-2 protects the cytokine from degradation. STK-009 does not bind to the wild type (WT) IL-2b receptor and does not activate IL-2-mediated signaling in bystander T and NK cells, thereby limiting systemic toxicity.",
  "synonyms": [
    "orthogonal IL-2 ligand STK-009",
    "orthogonal IL-2 STK-009",
    "orthoIL-2 STK-009",
    "pegylated IL-2 mutein STK-009"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pegylated-orthogonal-il-2-stk-009/"
}